Obsidian Therapeutics is developing a suite of technologies that allow for control of protein activity within cells to power novel therapeutics. This will allow them to deliver transformative outcomes for patients with previously intractable diseases.
Number of employees: 51 – 250
Location: Cambridge, MA, USA
Clunky ELN lacked features for biology
Previous ELN was clunky and didn’t allow for linkages to registered samples, hindering adoption and experimental detail.
Inefficient request fulfillment
Without a formal registration system, Obsidian scientists couldn’t draw connections between results, data, and upstream entities.
Low-adoption legacy sample tracking system
Legacy sample tracking system was unintuitive and saw low scientist usage, leading to data loss and compliance concerns.